Research Paper Volume 15, Issue 24 pp 14677—14702
Identification and validation of necroptosis-related gene signatures to predict clinical outcomes and therapeutic responses in acute myeloid leukemia
Figure 7. Exploration of the response of the necroptosis score to immunotherapy. (A) Spearman correlation analysis of tumor-infiltrating lymphocytes and necroptosis score. (B, C) Expression of PD-L1 and PD-1 in groups with a high necroptosis score (B) and low necroptosis score (C). (D–F) Tumor purity, immune score, and stromal score of necroptosis-score groups were analyzed and plotted. (G, H) Correlations between necroptosis and other immune checkpoints in AML. (I) Profile of the necroptosis score in the non-responder group and responder group. (J, K) Patients with a higher necroptosis score have a higher response to ICB in four independent ICB cohorts compassing of four cancer types.